Optimer, led by former Pfizer marketer Pedro Lichtinger, is also busting the bad record that new antibiotics have.

FORBES: Biotech Busts And Breakthroughs For September 2011

Thirteen percent of those on the Optimer drug had the infection return, compared with 24 percent of those on vancomycin.

FORBES: Optimer Gets NEJM Power

Optimer, a San Diego-based company with no marketed products, completed a marketing application to the U.S. Food and Drug Administration on Nov. 30.

FORBES: Optimer Gets NEJM Power